check_circleStudy Completed

Amyloid Cardiomyopathy

Bayer Identifier:
AG10-301
ClinicalTrials.gov Identifier:
NCT03860935
EudraCT Number:
Not Available
EU CT Number:
Not Available
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A

    Trial summary

    Enrollment Goal
    N/A
    Trial Dates
    March 2019 - May 2023
    Phase
    Phase 3
    Could I Receive a placebo
    N/A
    Products
    Acoramidis (BAY3684938)
    Accepts Healthy Volunteer
    N/A

    Trial design

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)
    Trial Type
    Interventional
    Intervention Type
    N/A
    Trial Purpose
    N/A
    Allocation
    N/A
    Blinding
    N/A
    Assignment
    N/A
    Trial Arms
    N/A